Kristina Schwamborn is a consultant at the Institute of Pathology, TU Munich, Germany. She received her M.D. from Heinrich-Heine-University in Dusseldorf, Germany. Dr. Schwamborn also holds a PhD from RWTH Aachen University for developing different proteomic assays in search for prostate and bladder cancer biomarkers. Between 2008-2010 she joined the group of Prof. Richard Caprioli in the Department of Biochemistry, Vanderbilt University to utilize imaging mass spectrometry in different clinical applications including diagnosis and risk stratification in prostate cancer. In 2010 she joined the Institute of Pathology, TU Munich and took her board examination in Anatomical Pathology in 2015.

Patrick Twomey is consultant chemical pathologist in St. Vincent's University Hospital, Dublin, the Laboratory Director for Clinical Chemistry in St Vincent’s University Hospital and Clinical Professor in the School of Medicine, University College Dublin. He obtained an Intercalated BSc in Biochemistry from University College Cork before being awarded his Medical degree. He is a Fellow of both the Faculty of Pathology at the Royal College of Physicians of Ireland and of the Royal College of Pathologists where he also is an examiner. He is the Vice Chair of the UK Joint Working Group on Quality Assessment in Pathology and past Chair of the Chemical Pathology National Quality Assurance Advisory Panel within the Royal College of Pathologists. He is the Honorary Treasurer of the Faculty of Pathology, Royal College of Physicians of Ireland and Honorary Treasurer of the Association of Clinical Pathologists. He has co-authored one text book, several book chapters and over 80 original publications in the fields of clinical biochemistry, metabolic medicine, lipids and nutrition. He is a member of the editorial boards of the Journal of Clinical Pathology and of the British Medical Journal Case Reports.

Professor of Haemostasis and Thrombosis, Barts and the London School of Medicine and Dentistry, Queen Mary University of London. Honorary Consultant Haematologist, The Royal London Hospital, Barts Health NHS Trust, London, UK.

John Pasi is Professor of Haemostasis and Thrombosis at The Royal London Hospital, Barts and the London School of Medicine and Dentistry and Haemophilia Centre Director.

His clinical practice spans both adults and children and covers all aspects of haemostasis and thrombosis. His research interests cover many aspects of inherited and acquired bleeding and clotting disorders, particularly new bioengineered therapies for haemophilia, novel therapies for haemophilia including gene therapy and RNAi technologies as well as the optimization of currently available therapies. He is closely involved in the design and development of clinical trials for new therapies and evolving phase 1-4 programmes. In addition, he has a major interest in the development of robust and harmonised outcome measures for haemophilia including application to research.

Professor Foster is the Professor of Hepatology at Queen Marys, University of London and a consultant at Barts Health in East London. He trained in Medicine at Oxford and London Universities in the 1980's and completed a PhD in Molecular Biology in 1992.  Professor Foster has a long standing interest in the management of chronic viral hepatitis and runs a clinical research program studying the natural history of viral hepatitis, its impact upon patients and their communities and novel therapies for this disease. He leads a national study investigating community screening for viral hepatitis and supervises a laboratory research program investigating novel replication models for hepatitis C.  He is the editor of The Journal of Viral Hepatitis and has published widely in the field of viral liver disease. He is a past President of BASL, Chairman of the NHSE Hepatobiliary Clinical Reference Group, Clinical Lead for the NHSE Hepatitis C Programme and a member of a number of patient advocacy groups.

Matt Loose has dedicated significant time and energy to the development of tools and techniques for the analysis of long-read nanopore sequence data. To demonstrate the feasibility of this sequencer for large genomes, Matt Loose was a key member of the Nanopore WGS consortium, which released the first 35x coverage dataset of the NA12878 Human Reference Genome sequence and RNA datasets (Nature Biotechnology 2018). He has since been working to extend ultra-long sequencing methods, now reaching reads up to 2Mb in length.

Tony is a practicing frontline NHS surgeon, Director of Medical Innovation at Anglia Ruskin University, and has founded 4 Med-Tech start-ups. He has also co-founded the £500m Anglia Ruskin MedTech Campus.

In 2014 he was appointed as National Clinical Director for Innovation at NHS England and in February 2016 became the first National Clinical Lead for Innovation. In this role he provides clinical leadership and support in delivering improved health outcomes in England and drives the uptake of proven innovations across the NHS, promotes economic growth through innovation and helps make the NHS the go to place on the planet for medical innovation. In 2015 he founded the NHS Clinical Entrepreneur programme. This has become the world’s largest entrepreneurial workforce development programme for clinicians.

After training as a Biomedical Scientist in hospital pathology, Stephen worked as a company microbiologist until 1996 when he joined the medical device regulator now known as the UK Medicines & Healthcare Products Regulatory Agency – MHRA.

Stephen is the chair of the European Commission’s IVD working group. This group is responsible for implementing IVD specific issues related to the new regulations including classification, performance evaluation, Common Specifications and advice and guidance on IVD regulatory issues.

Stephen is senior policy manager at MHRA focussing on the implementation of the new regulations for in vitro diagnostic medical devices.

Professor Shafi Ahmed is a multi award winning surgeon, teacher, futurist, innovator and entrepreneur. He is a 3x TEDx speaker and is faculty at Singularity University. He has delivered over 250 keynotes in 30 countries.

He is a cancer surgeon at The Royal London and St Bartholomew’s Hospitals and has been awarded the accolade of the most watched surgeon in human history. As a dedicated trainer, educator, and Associate Dean of Bart’s Medical School, he was awarded the Silver Scalpel award in 2015 as the best national trainer in surgery by the Association of Surgeons in Training. He is currently serving as an elected member of council of the Royal College of Surgeons of England where he is the Director of the International Surgical Training Programme. He is an honorary visiting professor at The University of Bradford where he delivered the Cantor Lecture of Technology in 2017 and the public lecture to open the Digital Health Enterprise Zone.

He has recently been appointed as CEO of SAMD University Hospital in Bolivia, the first Digital hospital in South America.

Professor Peter Hamilton has recently been appointed as Head of Research, Digital and Computational Pathology Philips and Lead for Image Analysis Hub in Belfast.  Prior to this Peter lead the digital pathology programme at Queen’s University Belfast and founded the company PathXL.  

Peter's research has focuses on digital pathology for education, computer vision and tissue bioimaging in diagnostic and molecular cancer pathology, and the high throughput quantitative analysis identification of novel tissue and cell biomarkers markers. Being a pioneer of early techniques in tissue measurement, image analysis, pathology informatics and tissue biomarker discovery, he has been published in over 120 peer reviewed publications and generated in access of £15m in grant funding to support pathology research.

Manoj is a Consultant Orthopaedic Surgeon in Paediatric and Young Adult Orthopaedics and Trauma at Barts Health, based at The Royal London and Barts and The London Children’s Hospitals, London, UK. He is also Honorary Reader at Queen Mary, University of London at the Institute of Bioengineering. He qualified from King’s College School of Medicine, London with a double honours degree and proxime accessit to the University of London Gold Medal and trained in London, Los Angeles and Sydney. He has published more than 100 papers in peer-reviewed journals (including the Lancet and BMJ) and written 18 books. His non-clinical interests include clinical trials, digital health, medical devices, innovation, and charitable work. He is the co-founder of Viz.ai, an artificial intelligence start-up in medical imaging. More about Manoj at manoj.strikingly.com.

Okan Ekinci, MD, MBA is the Chief Medical Officer of Roche Diagnostics Information Solutions (DIS), based in Basel, Switzerland. He is globally responsible for the Medical & Scientific Affairs of DIS, a unit that develops and offers services related to clinical decision support and data science in the context of personalized healthcare and digitalization. He brings along 20 years of experience in the healthcare sector, among which he has eight years of clinical practice in cardiology.

Okan is an adjunct professor for Advanced Cardiac Imaging at University College Dublin Medical School, Ireland, and lectures also on Med-Tech Marketing at University of Applied Sciences Rosenheim, Germany. Okan holds an MBA from the European School of Management and Technology, Berlin, Germany, and an MD from the University of Mainz, Germany. He studied medicine at University of Izmir (Turkey), University of Mainz (Germany) and University of Texas at Houston, TX (USA).

Chris joined Roche in 1998 as Marketing Manager, Patient Monitoring for UK & Ireland. This business unit included Diabetes and Point of Care products used in both the Hospital and the Community. In the last 16 years Chris has held a number of Senior Leadership positions with Roche both in the UK and Global organisation.

Chris is currently an Executive Committee member of BIVDA (British In Vitro Diagnostics Association) and the Diagnostic Industry Representative on the MTAC (Medical Technologies Advisory Committee) for NICE (National Institute for Health and Care Excellence.)

Sasha started his career in dentistry and maxillofacial surgery. Whilst learning about the intricacies of clinical care he found the challenges of how to organise a health system even more compelling. He spent more than 20 years working on integrated care in South Devon developing an internationally-recognised system. Realising that even this system would not be good enough to deal with the demographic and economic pressures facing us today he started to explore how to significantly improve health system productivity. This led to establishing a Health Innovation Education Cluster, working with the Nuffield Trust and working with the Horizons team to support teams delivering large scale transformation. Sasha combines his clinical, operational and strategic experience to design and facilitate large scale transformation programmes.

Bridget Wilkins is a consultant histopathologist who has been an enthusiastic champion of innovation throughout her career, from the emergence and automation of immunohistochemistry to the increasing application of molecular analysis in histology and the adoption of digital pathology. Through her increasing involvement with quality improvement in recent years, she has become particularly interested in the psychological and behavioural factors that influence successful adoption and spread of new technologies and ways of working.